The patent-pending methodology and surface chemistry used in the manufacture of Sona's Gemini and Omni gold nanorods makes them perfectly suited for both in-vitro and in-vivo applications.
• Lateral Flow Assays.
• Detect more than one biomarker.
• Distinct visual difference between test lines.
• Scalable and cost effective.
• Use as a carrier device to deliver payload(s) of drug molecules to cells, tissue, or organs.
• High efficiency of the GNRs for delivering pain relieving agents over other nanoparticles.
• Eliminates the genetic modification of target cells.
• Nanorods absorb in the near IR, and generate heat when excited with IR light.
• Nanorods can be conjugated with tumor targeting motifs and ingested. When a patient is exposed to IR light nanorods are locally heated, destroying only the cancerous tissue while leaving healthy cells intact.
• Gold bio-markers with plasmonic resonance have many advantages.
• Produce high image quality.
• Yield both qualitative and quantitative data.
• More intuitive for the health care practitioners to interpret.
Point of Care Testing
Point of care testing (POCT) is when a test is administered at the time of consultation with near-instant availability of results; allowing the practitioner to make immediate and informed decisions about patient care. Point of care testing allows a diagnosis to be made in the fastest possible manner, when traditional testing is typically conducted in a laboratory setting.
Where is POCT Done?
Point of care testing can be carried out at the bedside, or near the patient. Simplified, POCT is any testing performed in a healthcare environment which is not sent to a lab for results.
POCT can be performed in the following settings:
- Urgent Care Clinics
- General Practitioner’s Offices
- Mobile clinics
The advantage of Sona’s lateral flow test (LFT) in detecting COVID-19 is that results are achieved after 15 minutes, and the administration of the test does not require the specific expertise of a health care professional.